Abstract | BACKGROUND: OBJECTIVE: RESEARCH DESIGN AND METHODS: The authors searched for relevant references in the MEDLINE database and in congress abstracts of the American Society of Clinical Oncology. RESULTS:
Topotecan is an established second-line therapy for advanced and relapsed ovarian cancer; a regimen of 1.5 mg/m(2)/day 1-5 has been approved in the USA and many other western countries. Topotecan is well tolerated; associated haematological toxicity is generally manageable, reversible and non-cumulative. A number of alternative dosing regimens and formulations have been investigated in an attempt to improve the toxicity profile of topotecan without compromising anti-tumour activity. A novel oral formulation of topotecan has shown clinical promise in patients with advanced and relapsed disease. Administration of i.v. topotecan on a weekly basis produced encouraging results in several phase II trials, with less haematological toxicity and similar response rates to the day 1-5 regimen. Also, recent early studies demonstrate that topotecan is effective in combination with several other therapeutic agents in the relapsed setting. CONCLUSION: The peer-reviewed literature reports that topotecan is an effective, well tolerated treatment option for relapsed ovarian cancer.
|
Authors | Jalid Sehouli, Gülten Oskay-Ozcelik |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 25
Issue 3
Pg. 639-51
(Mar 2009)
ISSN: 1473-4877 [Electronic] England |
PMID | 19232038
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Topotecan
|
Topics |
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Ovarian Neoplasms
(drug therapy)
- Recurrence
- Topotecan
(administration & dosage, adverse effects, therapeutic use)
|